Lumen Bioscience
@lumenbio.bsky.social
Our patented technology allows us to use the well-known food algae spirulina to deliver therapeutic proteins.
🔬 Accelerating Cures
🌍 Expanding Access
🔬 Accelerating Cures
🌍 Expanding Access
Why can't we solve antibiotic resistance? Economics. Even FDA-approved drugs fail commercially. Preventive antimicrobials change the game—stopping infections before they start creates sustainable market economics while improving patient care. pharmatimes.com/magazine/2025/…
October 29, 2025 at 7:42 PM
Why can't we solve antibiotic resistance? Economics. Even FDA-approved drugs fail commercially. Preventive antimicrobials change the game—stopping infections before they start creates sustainable market economics while improving patient care. pharmatimes.com/magazine/2025/…
Welcome David Saunders, MD, MPH! U.S. Army Colonel & clinical trialist bringing key expertise as we advance LMN-201 to commercialization. https://www.lumen.bio/news/2025/10/08/lumen-bioscience-expands-board-and-leadership-team-to-advance-clinical-pipeline-of-novel-oral-biologics
October 15, 2025 at 3:02 PM
Welcome David Saunders, MD, MPH! U.S. Army Colonel & clinical trialist bringing key expertise as we advance LMN-201 to commercialization. https://www.lumen.bio/news/2025/10/08/lumen-bioscience-expands-board-and-leadership-team-to-advance-clinical-pipeline-of-novel-oral-biologics
Congrats to Kole Krieger on his promotion to SVP! His leadership is key as we prep for LMN-201's launch. https://www.lumen.bio/news/2025/10/08/lumen-bioscience-expands-board-and-leadership-team-to-advance-clinical-pipeline-of-novel-oral-biologics
October 14, 2025 at 3:02 PM
Congrats to Kole Krieger on his promotion to SVP! His leadership is key as we prep for LMN-201's launch. https://www.lumen.bio/news/2025/10/08/lumen-bioscience-expands-board-and-leadership-team-to-advance-clinical-pipeline-of-novel-oral-biologics
Congrats to Nhi Khuong, PhD on her promotion to EVP! Her leadership advancing our biologics platform is crucial as we prep for LMN-201's launch. https://www.lumen.bio/news/2025/10/08/lumen-bioscience-expands-board-and-leadership-team-to-advance-clinical-pipeline-of-novel-oral-biologics
October 13, 2025 at 3:02 PM
Congrats to Nhi Khuong, PhD on her promotion to EVP! Her leadership advancing our biologics platform is crucial as we prep for LMN-201's launch. https://www.lumen.bio/news/2025/10/08/lumen-bioscience-expands-board-and-leadership-team-to-advance-clinical-pipeline-of-novel-oral-biologics
Welcoming Jeff Raikes to our board! https://www.lumen.bio/news/2025/10/08/lumen-bioscience-expands-board-and-leadership-team-to-advance-clinical-pipeline-of-novel-oral-biologics
October 9, 2025 at 3:02 PM
Welcoming Jeff Raikes to our board! https://www.lumen.bio/news/2025/10/08/lumen-bioscience-expands-board-and-leadership-team-to-advance-clinical-pipeline-of-novel-oral-biologics
Welcoming Erik Anderson as Vice Chairman! The WestRiver Group & Singularity University CEO led our Series C and will help scale our spirulina-based biologics.
www.lumen.bio
October 8, 2025 at 11:02 AM
Welcoming Erik Anderson as Vice Chairman! The WestRiver Group & Singularity University CEO led our Series C and will help scale our spirulina-based biologics.
How can U.S. drug research maintain its competitive edge? Our CEO Brian Finrow, in collaboration with Sandeep Patel, explores solutions for accelerating American innovation.
Read their analysis here, published in @statnews.com.
www.statnews.com/2025/06/03/u...
Read their analysis here, published in @statnews.com.
www.statnews.com/2025/06/03/u...
4 ideas to kick-start U.S. drug research — and beat China in biotech
“There's no reason the U.S. can't pick up the pace to match the global clinical research front-runners without compromising safety,” write Brian Finrow and Sandeep Patel.
www.statnews.com
June 4, 2025 at 7:55 PM
How can U.S. drug research maintain its competitive edge? Our CEO Brian Finrow, in collaboration with Sandeep Patel, explores solutions for accelerating American innovation.
Read their analysis here, published in @statnews.com.
www.statnews.com/2025/06/03/u...
Read their analysis here, published in @statnews.com.
www.statnews.com/2025/06/03/u...
Our CEO Brian Finrow recently sat down with The Bio Report to discuss how Lumen is revolutionizing biologics production using algae (spirulina).
Listen to the full episode here: www.podbean.com/pw/pbblog-e7...
Listen to the full episode here: www.podbean.com/pw/pbblog-e7...
The Bio Report | Levine Media Group
The Bio Report podcast, hosted by award-winning journalist Daniel Levine, focuses on the intersection of biotechnology with business, science, and policy.
www.podbean.com
June 4, 2025 at 7:35 PM
Our CEO Brian Finrow recently sat down with The Bio Report to discuss how Lumen is revolutionizing biologics production using algae (spirulina).
Listen to the full episode here: www.podbean.com/pw/pbblog-e7...
Listen to the full episode here: www.podbean.com/pw/pbblog-e7...
Promising news for C. diff patients! 100% of patients with LMN-201 + antibiotics successfully resolved their primary infection, and 95% of participants had no recurrence within 28 days (RePreve Trial sentinel cohort results). www.lumen.bio/2025/04/02/l...
#MedSky
#MedSky
LMN-201 Achieves 100% Initial C. difficile Clinical Cure in Preliminary Cohort of RePreve Trial - Lumen Bioscience
Strong potential to disrupt market for treatment of C. diff infections RePreve Trial main cohort now recruiting Seattle, WA – April 3, 2025 – In a landmark achievement for its pioneering spirulina-bas...
www.lumen.bio
April 3, 2025 at 7:40 PM
Promising news for C. diff patients! 100% of patients with LMN-201 + antibiotics successfully resolved their primary infection, and 95% of participants had no recurrence within 28 days (RePreve Trial sentinel cohort results). www.lumen.bio/2025/04/02/l...
#MedSky
#MedSky